Literature DB >> 19417022

Chromosomal instability and copy number alterations in Barrett's esophagus and esophageal adenocarcinoma.

Thomas G Paulson1, Carlo C Maley, Xiaohong Li, Hongzhe Li, Carissa A Sanchez, Dennis L Chao, Robert D Odze, Thomas L Vaughan, Patricia L Blount, Brian J Reid.   

Abstract

PURPOSE: Chromosomal instability, as assessed by many techniques, including DNA content aneuploidy, loss of heterozygosity, and comparative genomic hybridization, has consistently been reported to be common in cancer and rare in normal tissues. Recently, a panel of chromosome instability biomarkers, including loss of heterozygosity and DNA content, has been reported to identify patients at high and low risk of progression from Barrett's esophagus (BE) to esophageal adenocarcinoma (EA), but required multiple platforms for implementation. Although chromosomal instability involving amplifications and deletions of chromosome regions have been observed in nearly all cancers, copy number alterations (CNA) in premalignant tissues have not been well characterized or evaluated in cohort studies as biomarkers of cancer risk. EXPERIMENTAL
DESIGN: We examined CNAs in 98 patients having either BE or EA using Bacterial Artificial Chromosome (BAC) array comparative genomic hybridization to characterize CNAs at different stages of progression ranging from early BE to advanced EA.
RESULTS: CNAs were rare in early stages (less than high-grade dysplasia) but were progressively more frequent and larger in later stages (high-grade dysplasia and EA), including high-level amplifications. The number of CNAs correlated highly with DNA content aneuploidy. Patients whose biopsies contained CNAs involving >70 Mbp were at increased risk of progression to DNA content abnormalities or EA (hazards ratio, 4.9; 95% confidence interval, 1.6-14.8; P = 0.0047), and the risk increased as more of the genome was affected.
CONCLUSIONS: Genome-wide analysis of CNAs provides a common platform for the evaluation of chromosome instability for cancer risk assessment as well as for the identification of common regions of alteration that can be further studied for biomarker discovery.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19417022      PMCID: PMC2684570          DOI: 10.1158/1078-0432.CCR-08-2494

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  52 in total

1.  Genomic alterations in malignant transformation of Barrett's esophagus.

Authors:  P H Riegman; K J Vissers; J C Alers; E Geelen; W C Hop; H W Tilanus; H van Dekken
Journal:  Cancer Res       Date:  2001-04-01       Impact factor: 12.701

Review 2.  Phases of biomarker development for early detection of cancer.

Authors:  M S Pepe; R Etzioni; Z Feng; J D Potter; M L Thompson; M Thornquist; M Winget; Y Yasui
Journal:  J Natl Cancer Inst       Date:  2001-07-18       Impact factor: 13.506

3.  DNA copy number profiling in esophageal Barrett adenocarcinoma: comparison with gastric adenocarcinoma and esophageal squamous cell carcinoma.

Authors:  A Varis; P Puolakkainen; H Savolainen; A Kokkola; J Salo; O Nieminen; S Nordling; S Knuutila
Journal:  Cancer Genet Cytogenet       Date:  2001-05

Review 4.  Systematic review: Cyclo-oxygenase-2 in human oesophageal adenocarcinogenesis.

Authors:  S Mehta; A Boddy; I T Johnson; M Rhodes
Journal:  Aliment Pharmacol Ther       Date:  2006-11-01       Impact factor: 8.171

5.  Predictors of progression in Barrett's esophagus III: baseline flow cytometric variables.

Authors:  P S Rabinovitch; G Longton; P L Blount; D S Levine; B J Reid
Journal:  Am J Gastroenterol       Date:  2001-11       Impact factor: 10.864

6.  Long-term nonsurgical management of Barrett's esophagus with high-grade dysplasia.

Authors:  T G Schnell; S J Sontag; G Chejfec; G Aranha; A Metz; S O'Connell; U J Seidel; A Sonnenberg
Journal:  Gastroenterology       Date:  2001-06       Impact factor: 22.682

7.  Genetic differences between adenocarcinomas arising in Barrett's esophagus and gastric mucosa.

Authors:  W El-Rifai; H F Frierson ; C A Moskaluk; J C Harper; G R Petroni; E A Bissonette; D R Jones; S Knuutila; S M Powell
Journal:  Gastroenterology       Date:  2001-09       Impact factor: 22.682

8.  Chromosomal imbalances in Barrett's adenocarcinoma and the metaplasia-dysplasia-carcinoma sequence.

Authors:  A K Walch; H F Zitzelsberger; J Bruch; G Keller; D Angermeier; M M Aubele; J Mueller; H Stein; H Braselmann; J R Siewert; H Höfler; M Werner
Journal:  Am J Pathol       Date:  2000-02       Impact factor: 4.307

9.  Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation.

Authors:  E Montgomery; M P Bronner; J R Goldblum; J K Greenson; M M Haber; J Hart; L W Lamps; G Y Lauwers; A J Lazenby; D N Lewin; M E Robert; A Y Toledano; Y Shyr; K Washington
Journal:  Hum Pathol       Date:  2001-04       Impact factor: 3.466

Review 10.  Genetic pathways involved in the progression of Barrett's metaplasia to adenocarcinoma.

Authors:  G J S Jenkins; S H Doak; J M Parry; F R D'Souza; A P Griffiths; J N Baxter
Journal:  Br J Surg       Date:  2002-07       Impact factor: 6.939

View more
  49 in total

1.  Medical and endoscopic management of high-grade dysplasia in Barrett's esophagus.

Authors:  K K Wang; J M Tian; E Gorospe; J Penfield; G Prasad; T Goddard; M Wongkeesong; N S Buttar; L Lutzke; S Krishnadath
Journal:  Dis Esophagus       Date:  2012-03-12       Impact factor: 3.429

Review 2.  Early events during neoplastic progression in Barrett's esophagus.

Authors:  Brian J Reid
Journal:  Cancer Biomark       Date:  2010       Impact factor: 4.388

3.  Barrett's Esophagus: A Review of Biology and Therapeutic Approaches.

Authors:  Panteleimon Kountourakis; Jaffer A Ajani; Marta Davila; Jeffrey H Lee; Manoop S Bhutani; Julie G Izzo
Journal:  Gastrointest Cancer Res       Date:  2012-03

4.  The microRNAs, MiR-31 and MiR-375, as candidate markers in Barrett's esophageal carcinogenesis.

Authors:  Rom S Leidner; Lakshmeswari Ravi; Patrick Leahy; Yanwen Chen; Beth Bednarchik; Mirte Streppel; Marcia Canto; Jean S Wang; Anirban Maitra; Joseph Willis; Sanford D Markowitz; Jill Barnholtz-Sloan; Mark D Adams; Amitabh Chak; Kishore Guda
Journal:  Genes Chromosomes Cancer       Date:  2012-02-03       Impact factor: 5.006

5.  New strategies in Barrett's esophagus: integrating clonal evolutionary theory with clinical management.

Authors:  Brian J Reid; Rumen Kostadinov; Carlo C Maley
Journal:  Clin Cancer Res       Date:  2011-04-15       Impact factor: 12.531

Review 6.  Biomarkers of Barrett's esophagus.

Authors:  Yasser Mahrous Fouad; Ibrahim Mostafa; Reem Yehia; Hisham El-Khayat
Journal:  World J Gastrointest Pathophysiol       Date:  2014-11-15

Review 7.  Genetic Insights in Barrett's Esophagus and Esophageal Adenocarcinoma.

Authors:  Brian J Reid; Thomas G Paulson; Xiaohong Li
Journal:  Gastroenterology       Date:  2015-07-21       Impact factor: 22.682

Review 8.  From genetics to signaling pathways: molecular pathogenesis of esophageal adenocarcinoma.

Authors:  Ravindran Caspa Gokulan; Monica T Garcia-Buitrago; Alexander I Zaika
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2019-05-30       Impact factor: 10.680

Review 9.  Long Noncoding RNAs in the Pathogenesis of Barrett's Esophagus and Esophageal Carcinoma.

Authors:  John M Abraham; Stephen J Meltzer
Journal:  Gastroenterology       Date:  2017-05-18       Impact factor: 22.682

10.  Targeting chemokine pathways in esophageal adenocarcinoma.

Authors:  Makardhwaj S Shrivastava; Zulfiqar Hussain; Orsolya Giricz; Niraj Shenoy; Rahul Polineni; Anirban Maitra; Amit Verma
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.